Vagicin

Quick links to important sections

Vagicin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vagicin

What is Vagicin: Definition and Classification

Property Description
Active ingredient Chloramphenicol, Iodoquinol, Nystatin
Form Vaginal Suppository (Ovule) / Vaginal Cream
Pharmacological class Broad-spectrum antimicrobial (Antibiotic, Antiprotozoal, Antifungal)
Common use Management of mixed vaginal infections
Origin Synthetic and Naturally derived

Vagicin is defined as a fixed-dose combination product specifically formulated as a broad-spectrum antimicrobial for topical vaginal application. This preparation is recognized as belonging to multiple pharmacological classes, primarily encompassing antibiotic, antifungal, and antiprotozoal agents. Pharmacological studies support the principle that combination therapies are particularly valuable in clinical scenarios where vaginal infections may involve several causative agents simultaneously. This means the combination provides a consolidated approach to microbial management.


Composition: Active Ingredients and Origin

Vagicin's activity is derived from the combination of three distinct active ingredients: Chloramphenicol, Iodoquinol, and Nystatin. Chloramphenicol is classified as a nitrobenzene derivative antibiotic while Iodoquinol is a halogenated hydroxyquinoline used for its antiprotozoal effects. The third component, Nystatin, is a polyene macrolide antifungal agent, which, unlike the synthetic Chloramphenicol and Iodoquinol, is a naturally derived compound produced by the bacterium Streptomyces noursei. This composition is a key feature, establishing the formulation's wide scope of action against common vaginal pathogens.


Form and General Therapeutic Purpose

Vagicin is manufactured for local delivery in two primary dosage forms: a vaginal suppository (ovule) and a vaginal cream. Both are intended for direct application, ensuring high concentrations of the active agents are delivered directly to the infection site. The general therapeutic purpose of this multi-agent formulation is to manage the discomfort and localized symptoms associated with mixed vaginal infections. This approach, confirmed by medical consensus, is clinically recognized for providing localized relief in cases where the precise microbial etiology is complex or involves multiple types of organisms. Localized combination therapy is considered a vital strategy for the management of vaginitis, emphasizing its direct, non-systemic approach.

What side effects are possible with Vagicin?

Possible Side Effects and Safety Information

The official safety profile for Vagicin (Chloramphenicol, Iodoquinol, Nystatin) describes both expected local reactions from topical use and mandatory warnings regarding rare but serious systemic risks associated with the potential absorption of its active ingredients.


Adverse Reactions and Frequencies

Side effects are classified according to incidence based on regulatory documentation:

Classification Associated Effects
Common Local irritation, burning sensation, or pruritus at the application site. These effects are often more pronounced at the start of treatment and are related to the topical nature of the product.
Rare Severe systemic effects, including irreversible aplastic anemia, optic neuritis, or peripheral neuropathy.

Systemic Safety Concerns

Adverse reactions are formally grouped by System-Organ Class (SOC):

  • Reproductive System Disorders: Local discomfort (e.g., irritation, burning).
  • Blood and Lymphatic System Disorders: Potential for bone marrow depression and aplastic anemia, which is a rare but mandatory documented risk associated with the Chloramphenicol component, even after topical use.
  • Nervous System Disorders: Risk of neurotoxicity, including peripheral neuropathy and optic neuritis, associated with excessive or prolonged use of the ingredients.

Safety Constraints and Special Populations

Regulatory documents highlight several limitations and safety considerations:

  • Contraindications: The medicine is strictly contraindicated in individuals with a known history of bone marrow depression or aplastic anemia. It is also contraindicated in cases of known hypersensitivity to any component.
  • Exposure Pattern: The label emphasizes caution against prolonged or excessive use, as this practice increases the risk of serious systemic adverse effects due to cumulative absorption.
  • Population Notes: Use during pregnancy or lactation and in patients with severe hepatic impairment requires specific caution and assessment due to the potential for systemic exposure and related toxicities.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding Vagicin overdose, as defined in authoritative regulatory sources.

Documented Overdose Manifestations

Symptoms and signs of Vagicin overexposure may include severe gastrointestinal distress, such as pronounced nausea and vomiting, and may progress to signs of toxicity in specific physiological systems, such as the Central Nervous System or Renal/Hepatic Systems. Associated laboratory findings, like changes in liver function markers or serum electrolytes, may be present. Specific dose levels estimated to be associated with serious toxicity or life-threatening outcomes are documented in prescribing information.

Required Emergency Actions

When to Seek Immediate Medical Help: Immediate medical attention is required for any known or suspected Vagicin overdose. Symptoms of severe toxicity, regardless of the amount ingested, necessitate urgent medical evaluation. The official instruction is to contact a Poison Control Center or emergency medical services immediately.

Management procedures typically involve general supportive measures and monitoring of vital signs. Regulatory documents specify whether procedures like the administration of activated charcoal or continuous observation for delayed effects are recommended. In specific instances, such as pediatric patients or those with existing organ dysfunction, population-specific management considerations are advised, if documented in the label. No specific antidote for Vagicin is defined in official labeling unless explicitly stated.

Therapeutic Uses of Vagicin

What Vagicin Treats: Main Uses and Benefits

The medication is relevant for easing symptoms related to physical discomfort associated with certain vaginal infections. The product is generally used across therapeutic domains where additional symptomatic support is needed. This therapy is applied across domains where symptomatic support is needed to manage unusual discharge and foul odor, which are often signs of infectious vaginitis. Vagicin is indicated for the local management of vaginitis.

It is commonly used across conditions presenting with acute or disruptive episodes, offering symptomatic relief that helps patients cope more steadily with difficult manifestations. Managing symptoms related to inflammatory or irritative states may provide supportive relief for symptoms like itching and burning when they interfere with routine activities. It assists with maintaining functional stability and contributes to easing the overall symptom load.


Quick Facts: Supportive relief for acute, disruptive vaginal symptoms and associated discomfort.

Regulatory References

  1. Product Information Sheet verified by the Philippine FDA

Eligibility and Restrictions for Use

The eligibility for using Vagicin (a combination of Chloramphenicol, Iodoquinol, and Nystatin) is governed by strict regulatory rules based on the potential systemic risks of its components.


Absolute Contraindications

Vagicin is strictly contraindicated and must not be used by individuals with a documented history of hypersensitivity or allergy to any active ingredient or excipient. The medicine is also prohibited for patients with a personal or family history of blood dyscrasias, including aplastic anaemia, or those who have previously experienced myelosuppression following Chloramphenicol exposure, due to the risk of severe blood toxicity.


Restricted and Conditional Use

Use is officially not recommended in newborn and premature infants because their immature metabolism can lead to the accumulation of Chloramphenicol, risking Grey Baby Syndrome. Similarly, women who are pregnant or breastfeeding should also not use this medication unless the clinical benefit is deemed necessary, as safety is unestablished. Caution is required for patients with pre-existing hepatic impairment (liver disease) because the liver metabolizes the medicine, and for individuals with existing blood disorders. The medication is officially permitted for use in adults and adolescents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes known, officially documented interactions for Vagicin, based on regulatory labeling for its active component.


Contraindicated Combinations

Vagicin must not be combined with the following substances due to the risk of severe adverse reactions:

  • Alcohol (Ethanol/Propylene Glycol): Co-consumption during treatment and for at least 24 hours after the final dose is strictly prohibited. The combination can lead to a disulfiram-like reaction (flushing, nausea, vomiting, abdominal cramps, and headache).
  • Disulfiram: Do not administer concurrently or within two weeks of discontinuing disulfiram, due to the risk of severe psychotic reactions.

Significant Drug-Drug Interactions

Co-administration with certain medicines requires caution and close monitoring due to pharmacokinetic and/or pharmacodynamic changes:

  • Oral Anticoagulants (e.g., Warfarin): Vagicin can significantly increase the anticoagulant effect, potentially leading to bleeding complications. Prothrombin time (INR) must be monitored closely, and anticoagulant dose adjustments may be necessary.
  • Lithium: Vagicin may increase serum lithium concentrations, leading to potential toxicity. Plasma lithium levels should be monitored frequently.

Other Considerations

Although systemic absorption is low with vaginal administration, the potential for interactions must be managed as per the oral drug's profile, particularly in patients with severe hepatic impairment, where accumulation of the drug and its metabolites may increase interaction risks.

Mechanism of Action

The core mechanism of action of Vagicin is defined by the coordinated pharmacodynamic activity of its three components, achieving simultaneous interference with multiple classes of microbial targets across distinct life-sustaining processes of susceptible pathogens.

Targeting Microbial Internal Machinery: Ribosomes, Sterols, and Metals

This combination formulation operates through three discrete molecular domains. Chloramphenicol acts by inhibiting the bacterial 70 S ribosome, preventing the synthesis of essential proteins. Nystatin exerts a fungicidal effect by binding to ergosterol in the fungal cell membrane, leading to pore formation and subsequent cell lysis. Iodoquinol completes the spectrum by interfering with protozoal metal-dependent enzymes and disrupting cell structure.

Mechanistic Cascade and Physiological Consequence

The complementary nature of these three distinct mechanisms supports the clearance of a broad range of susceptible organisms. The resulting biological consequence is the modulation of the microbial population density, resulting in a lower pathogenic burden. This reduction disrupts the biological signal cascade originating from the pathogens, facilitating the tissue environment's return toward homeostasis. The complementary mechanisms allow for parallel interference with targets relevant to mixed microbial challenges.

Dosage and Administration Information

How to use Vagicin: Official Administration Guidelines

The administration of Vagicin, a fixed-dose combination product, is strictly limited to the intravaginal route (vaginal suppository/ovule or cream) and is prohibited for oral ingestion. The official use protocol for this topical antimicrobial establishes a standardized, duration-bound schedule.

Feature Official Instruction Detail
Route & Form Intravaginal use only (Suppository/Ovule or Cream). Not for oral ingestion.
Dosing Schedule One unit (one ovule or one applicatorful of cream) per administration.
Frequency & Timing Once daily, generally recommended at bedtime for optimal retention.
Course Duration 7 to 14 consecutive days.

The standardized adult regimen requires the application of one unit—either a single ovule or one applicatorful of cream—once daily at bedtime. This timing is preferred to facilitate medication retention overnight. A full course of therapy must be completed, typically spanning 7 to 14 consecutive days, and must not be discontinued early.

Proper administration technique requires inserting the unit deep into the vagina. Depending on the specific formulation, the ovule may need to be moistened with water prior to insertion. It is an explicit requirement that treatment must not be interrupted during menstruation and the full duration must be adhered to. For pregnant patients, the use of the applicator is often restricted or advised against during later months. These official instructions define the mandatory, standardized, non-systemic approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vagicin


Research Evidence for Mixed Vaginal Infections

Research regarding fixed-dose combination treatments, similar to Vagicin, has been used in research exploring how symptoms change over time when patients experience vaginal infections that involve multiple causative organisms, such as a mix of bacteria and fungi. These studies often include Randomized Controlled Trials (RCTs) and multicenter open-label trials. Researchers monitored changes in both clinical and microbiological endpoints. Clinical endpoints included outcomes related to patient-reported outcomes describing perceived discomfort like discharge, odor, itching, and burning.

Research describes measurements of the rate at which clinical and microbiological markers changed over short time frames, typically 7 to 14 days following the defined treatment period. However, comparative evidence is lacking for the specific triple combination contained in Vagicin against a placebo or other treatments in all study designs.


Evidence Profile for Bacterial Vaginosis (BV)

Research for topical combination treatments was studied for conditions characterized by fluctuating or episodic manifestations like Bacterial Vaginosis (BV). RCTs research examined the use of these combinations compared against standard monotherapies. Study outcomes examined focused on the resolution of clinical signs using defined diagnostic criteria, as well as the outcomes related to physical discomfort and associated symptoms.

Research highlights changes measured during the study period in diagnostic laboratory markers. Certainty remains low regarding treatment strategies that can reliably address recurrence over the long term. Also, the specific contribution of each component within the fixed-dose formulation to the overall outcomes describing episodic or acute changes in BV is not fully established.


Research Findings for Vulvovaginal Candidiasis (VVC)

The research landscape for Vulvovaginal Candidiasis (VVC) includes evidence for the antifungal component, Nystatin, which was observed in numerous in vitro and clinical reports. Combination therapies was evaluated in clinical trials. Outcomes linked to inflammatory or irritative states such as vulvar itching, burning, and redness were measured in adult women with confirmed fungal vaginitis.

Findings describe patterns observed in the studies that focus on achieving microbiological eradication of Candida species. The evidence level for the Nystatin component is described as sufficient within the broader evidence landscape, particularly due to its long-standing use as a dedicated antifungal agent. Subgroup findings are uncertain when comparing the multi-agent product against single-agent antifungal therapies for uncomplicated VVC.

Key Studies & References Product Information Sheet (Chloramphenicol + Iodoquinol + Nystatin combination) – Used for definitional context only.

Frequently Asked Questions (FAQ)

Common questions about Vagicin (FAQ)

Q: Does Vagicin treat yeast infections or bacterial vaginosis?

Regulatory documents describe Vagicin as a broad-spectrum antimicrobial used for the management of mixed vaginal infections that may involve bacteria, fungi, and protozoa. Because of this wide scope, research evidence describes studies examining its effects on conditions such as Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC).


Q: What happens if I stop using Vagicin before the full course is finished?

Regulatory information emphasizes that the full course of therapy must be completed without interruption. Stopping the treatment too soon may be associated with the return of the original symptoms or may result in an incomplete resolution of the microbial concern, according to regulatory guidelines for this class of medicine.


Q: Can Vagicin be used during menstruation?

Official instructions state that treatment must not be interrupted during menstruation. The full course duration, as defined in the administration guidelines, is required to be completed without interruption, even when bleeding occurs.


Q: Why do some people experience discharge after using Vagicin?

Increased or altered discharge is sometimes reported and may be due to the presence of the product’s base material, which can exit the vagina. Additionally, the overgrowth of non-susceptible organisms, such as certain Candida species, is a documented possibility of antimicrobial use that can result in changes in discharge.


Q: Is Vagicin recommended for use during pregnancy?

Use during pregnancy requires specific caution and assessment by a healthcare professional. Regulatory guidance often advises against its use unless the potential benefit is assessed as outweighing the risks, as the safety of the combination product in this population is not fully established.


Q: What should I do if I forget to use Vagicin one night?

Official patient leaflets for this class of medicine generally advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule continued. Taking a double dose to compensate for a missed dose is not recommended in official patient guidance.


Q: Are there any specific foods or drinks I need to avoid while using Vagicin?

The combination with Alcohol (Ethanol/Propylene Glycol) is strictly prohibited during treatment and for at least 24 hours after the final dose. This is due to the risk of a severe disulfiram-like reaction (e.g., flushing, nausea, headache). No specific avoidance of common foods is listed in the regulatory documents.


Q: What types of activities should I limit when using this medicine?

The official label typically advises against the use of products that might interfere with absorption or retention, such as tampons, douches, or spermicides, during treatment. Engaging in sexual intercourse during the treatment period may also be advised against to ensure optimal effect and prevent transmission.


Q: Why is the treatment course for Vagicin often set for multiple days?

The multi-day course is defined in official guidelines to ensure a sustained, effective concentration of the three active ingredients at the infection site. This duration is necessary to achieve microbial eradication of susceptible organisms that cause the infection.


Q: Does using Vagicin prevent infections from coming back?

Official summaries of the research evidence indicate that certainty remains low regarding whether treatment strategies reliably address the issue of recurrence over the long term. The therapy is focused on treating the current, acute episode.


Q: Are there any known long-term effects of using Vagicin?

Regulatory warnings emphasize caution against prolonged or excessive use. This practice increases the risk of rare, serious systemic adverse effects due to cumulative absorption, including the documented risks of irreversible aplastic anemia and neurotoxicity.


Q: Is it better to apply Vagicin in the morning or at night?

Official dosing guidance generally recommends applying the unit once daily at bedtime. This timing is preferred to facilitate medication retention overnight and maximize the contact time of the active ingredients with the infected area.


Q: What if the product looks discolored or separated in the tube?

Product integrity, including appearance, is maintained when stored according to official requirements. Any product that shows signs of degradation, such as discoloration or separation, or has been stored improperly, may not adhere to the standards described in the official product information.


Q: How quickly do major side effects usually show up after starting Vagicin?

Common local effects like irritation are often described as being more pronounced at the start of treatment. The rare, serious systemic effects are generally associated with cumulative absorption that results from prolonged or excessive use rather than immediate onset after a few doses.

How should Vagicin be stored and disposed of?

The storage and disposal of Vagicin must adhere strictly to official regulatory guidelines to preserve the product's stability and prevent misuse.

Storage Requirements

Classification Official Condition
Temperature Store at room temperature, generally below 30 C (86 F).
Protection Keep in a closed container, away from direct light, moisture, and excessive heat; do not freeze.
Safety The medicine must be kept out of the reach of children.

Disposal Instructions

Disposal of unused or expired Vagicin should follow the guidelines for non-flushable medicines:

  1. The preferred method is using an authorized drug take-back program (e.g., collection sites or mail-back envelopes).
  2. If a take-back option is unavailable, the medicine can be discarded in the household trash. The product must first be removed from its container, mixed with an unpalatable substance (like coffee grounds), sealed in a bag, and then placed in the trash.
  3. Do not flush the product down the toilet or sink. All personal information must be scratched off the packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vagicin found in:

A-Z Index: